A Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/II A Cervical cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy

About this Study

The purpose of this study is to find out if weekly cisplatin and concurrent radiation therapy increases the time participant's time without disease compared to radiation therapy alone.

Sponsor Protocol ID:GOG 263
IRB Number:2010-0249
Actively Enrolling
Phase 3
May 28, 2019
Eligibility Criteria
18 years old
Both Male and Female

Inclusion Criteria
1.  Patients should not be randomized less than 3 weeks post-surgery but will not be acceptable for randomization more than 8 weeks post-surgery.

2.  Patients who have met the pre-entry requirements.

3.  Patients must have signed an approved informed consent and authorization permitting release of personal health information.

4.  Patients must be > 18 years of age

Exclusion Criteria
  1. Patients with cervix cancer who have received any previous radiation or chemotherapy.
  2. Patients whose circumstances do not permit completion of the study or the required follow-up.
  3. Patients with a history of other invasive malignancies, with the exception of non-malignancy being present within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.

Categories Click category to view its trials.
Participating Locations
Cancer Center and Research Institute
Contact Information
Contact Name: Maggie Goad
Phone Number: 601-984-2700
Email: mgoad@umc.edu
Principal Investigator:Collier, Anderson B, M.D.
How to participate in our Clinical Trials